Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084985 | 0.86 | PYGM (0.67) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL3071099 | 0.81 | PYGM (0.55) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL3469958 | 0.77 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL10163545 | 0.77 | PYGM (0.61) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL9796913 | 0.77 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL15336891 | 0.77 | PYGM (0.61) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL28372181 | 0.77 | DNPH1 (0.74) | PYGMP2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL21888354 | 0.77 | P2RY6 (0.59) | PYGMP2RY6DNPH1P2RY14NT5E | |
| SCHEMBL1172397 | 0.76 | TYMS (0.54) | — | |
| SCHEMBL31685257 | 0.74 | DNPH1 (0.55) | PYGMP2RY6P2RY2DNPH1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465734-B2 | Methods and compositions for overcoming resistance to biologic and chemotherapy | CELMED ONCOLOGY (USA), INC. (CA) | 2008-12-16 | — | — | US | claimed |